Literature DB >> 9266445

Immunoreactivity of human MAb BT32/A6 with neuroepithelial tumors.

M D Dan1, P K Maiti, X He, G Y Gillespie, W C Halliday, A K Prashar, A D Friesen, H A Kaplan.   

Abstract

The present study was undertaken to determine the pattern of immunoreactivity of BT32/A6, a human IgM monoclonal antibody (MAb), with the following histological panels: 1) 30 human and non-human cell lines, 2) 32 normal human tissues, and 3) 28 tumors of central neuroepithelial origin (16 astrocytic; 11 non-astrocytic). Antibody BT32/A6 recognizes a surface and cytoplasmic antigen present on a variety of human tumor cell lines including gliomas, melanomas, neuroblastomas, and a few sarcomas. The antigen is present (at least focally) on 15/16 astrocytic tumor tissue sections (94%), and in some cases, on close to 100% of cells. All malignant cell types, including small anaplastic cells, giant cells, gemistocytic cells, and cells forming pseudopalisades were labeled by MAb BT32/A6. Non-astrocytic neuroepithelial tumors did not stain appreciably with MAb BT32/A6. There was weak immunoreactivity in a small subset of normal human tissues of epithelial and lymphoid origin, with the exception of adrenal cortex, which exhibited weak to moderate staining. All normal tissues of neuroectodermal and mesenchymal origin were unreactive. In conclusion, MAb BT32/A6 appears to be unique in that it recognizes a highly-expressed astrocytic tumor-associated antigen that is present on both low and high grade tumors. This makes it a strong candidate for further studies aimed at establishing its usefulness in the treatment of human astrocytic tumors.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9266445     DOI: 10.1023/a:1005826625813

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  15 in total

Review 1.  Integrative treatment of gliomas.

Authors:  K Sano
Journal:  Clin Neurosurg       Date:  1983

2.  Monoclonal antibodies against human astrocytomas and their reactivity pattern.

Authors:  D Stavrou; E Keiditsch; F Schmidberger; K Bise; I Funke; W Eisenmenger; R Kurrle; B Martin; U Stocker
Journal:  J Neurol Sci       Date:  1987-09       Impact factor: 3.181

3.  Serological analysis of cell surface antigens of malignant human brain tumors.

Authors:  M Pfreundschuh; H Shiku; T Takahashi; R Ueda; J Ransohoff; H F Oettgen; L J Old
Journal:  Proc Natl Acad Sci U S A       Date:  1978-10       Impact factor: 11.205

Review 4.  Monoclonal antibodies in neuro-oncology.

Authors:  D Stavrou
Journal:  Neurosurg Rev       Date:  1990       Impact factor: 3.042

Review 5.  Patterns of antigenic expression of human glioma cells.

Authors:  P E McKeever; R D Davenport; P Shakui
Journal:  Crit Rev Neurobiol       Date:  1991

6.  Phase I studies of treatment of malignant gliomas and neoplastic meningitis with 131I-radiolabeled monoclonal antibodies anti-tenascin 81C6 and anti-chondroitin proteoglycan sulfate Me1-14 F (ab')2--a preliminary report.

Authors:  D D Bigner; M Brown; R E Coleman; A H Friedman; H S Friedman; R E McLendon; S H Bigner; X G Zhao; C J Wikstrand; C N Pegram
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

7.  Antigenic and differentiative heterogeneity among human glioblastomas.

Authors:  G E Gillaspy; R H Miller; D Samols; D A Goldthwait
Journal:  Cancer Lett       Date:  1993-02       Impact factor: 8.679

8.  Antigenic heterogeneity of human brain tumors defined by monoclonal antibodies.

Authors:  D Stavrou; K Bise; J Groeneveld; U Stocker; H A Kretzschmar; E Keiditsch; P Mehraein
Journal:  Anticancer Res       Date:  1989 Nov-Dec       Impact factor: 2.480

Review 9.  Human immune response to monoclonal antibodies.

Authors:  M B Khazaeli; R M Conry; A F LoBuglio
Journal:  J Immunother Emphasis Tumor Immunol       Date:  1994-01

Review 10.  The biology of malignant gliomas--a comprehensive survey.

Authors:  R D McComb; D D Bigner
Journal:  Clin Neuropathol       Date:  1984 May-Jun       Impact factor: 1.368

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.